Digest Network Come funziona
Network
/
Società
Ro
Non verificato

Rondo Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
03/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody Targeting Nectin-4 in Advanced Solid Tumors
Fonte
Rondo Therapeutics
Emittente
Business Wire
1.00
0
08/04/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer
Fonte
Rondo Therapeutics
Emittente
Business Wire
1.00
0
10/02/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer
Fonte
Rondo Therapeutics
Emittente
Business Wire
1.00
0
04/12/2024
Mercato del lavoro
Industria
Scienza
Medicina - Varie
Biologia
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors
Fonte
Rondo Therapeutics
Emittente
Business Wire
1.00
0
19/11/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs
Fonte
Rondo Therapeutics
Emittente
Business Wire
1.00
0
02/07/2024
Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics
Fonte
Rondo Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0